Health
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
Abbott (NYSE: ABT) today announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) acute clinical feasibility study, which demonstrated the safety and performance of the investigational AVEIR CSP leadless pacemaker technology. The AVEIR CSP acute clinical feasibility study is the world's first assessment of a leadless pacemaker delivering conduction pacing to the heart's left bundle branch (LBB) area. CSP is a novel pacing approach that targets the LBB area by enabling pacing t
About this update from Abbott Laboratories
[{"type":"list","items":[{"val":[{"type":"text","content":"Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) lead","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Conduction System Pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural electrical rhythm","length":174,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":521,"olType":false},{"type":"text","content":"SAN DIEGO, April 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) acute clinical feasibility study, which demonstrated the safety and performance of the investigational AVEIR CSP leadless pacemaker technology. The AVEIR CSP acute clinical feasibility study is the world's first assessment of a leadless pacemaker delivering conduction pacing to the heart's left bundle branch (LBB) area. CSP is a novel pacing approach that targets the LBB area by enabling pacing that mimics the heart's natural electrical rhythm.","length":613,"tagName":"p"},{"type":"text","content":"The results were presented as a late-breaking clinical trial at the Heart Rhythm Society's (HRS) 46th annual meeting in San Diego (April 24-27, 2025) and simultaneously published in the Heart Rhythm Journal.","length":211,"tagName":"p"},{"type":"text","content":"The AVEIR CSP acute clinical feasibility study demonstrated successful implantation of the AVEIR CSP leadless pacemaker deep into the wall separating the left and right chambers of the heart, many achieving left bundle branch area pacing (LBBAP). All study participants received the AVEIR ventricular (VR) leadless pacemaker at the end of the procedure.","length":353,"tagName":"p"},{"type":"text","content":""For the first time, we have successfully demonstrated the feasibility of a leadless pacing system to facilitate conduction system pacing in the left bundle branch area of the heart, offering a novel approach to ...